Martin Shkreli
-
Blue Cross settles class action suit naming ‘pharma bro’ Martin Shkreli for $28M
Shkreli controversially raised the price of the drug Daraprim, which is used to treat a potentially fatal parasitic infection, by 4,000%, from $13.50 to $750 per pill in 2015. In January, a federal judge banned him from the pharmaceutical industry for life.
-
Insurers sue ‘pharma bro’ Martin Shkreli, company for alleged price gouging
Blue Cross and Blue Shield of Minnesota has filed a class-action lawsuit — on behalf of itself and insurers from 30-plus states — against Martin Shkreli and Vyera Pharmaceuticals. The suit alleges the defendants intentionally monopolized the market for Daraprim to raise the price of the drug by more than 4,000%.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Sorry, Martin Shkreli: FDA approves first generic version of Daraprim
The drug, used to treat toxoplasmosis infection, became the subject of notoriety in 2015 when manufacturer Turing Pharmaceuticals, then led by Shkreli, raised the price from $13.50 to $750 per pill, making it a poster child for the issue of high drug prices.
-
Another company took an old drug and jacked up the price. Now, biotech CEOs are throwing shade
Led by Codiak BioSciences CEO Douglas Williams, the CEOs criticized Belcher Pharmaceuticals, which won approval for a drug used in certain heart procedures through the FDA’s 505(b)(2) pathway.
-
Martin Shkreli, his former company thwarted generic competition against toxoplasmosis drug, FTC says
In charges announced Monday, the agency says Vyera Pharmaceuticals – formerly Turing Pharma – used deals with distributors to prevent generic companies from obtaining samples and sales data for Daraprim. Vyera called the charges meritless.
-
Report: Martin Shkreli runs his latest drug company from prison
The Wall Street Journal reported Thursday that the infamous former Turing Pharmaceuticals CEO was running the company with the aid of a contraband mobile phone.
-
HHS proposes allowing some drug importation, but impact would be limited
Nevertheless, the proposed policy could take Martin Shkreli-like practices “out of the ballgame,” expert says.
-
Martin Shkreli’s in prison but Daraprim prices are still high
Shkreli, 35, is serving a seven-year prison term for securities fraud (unrelated to Daraprim). Turing has renamed itself Vyera Pharmaceuticals. But Daraprim, which costs pennies to make and is used to treat the parasitic infection toxoplasmosis still retails for more than $750 per pill, according to drug website GoodRx.com.
-
Pharma karma catches up: Shkreli sentenced to 7 years
Judge Kiyo Matsumoto has sentenced the poster child for pharmaceutical company greed to seven years after a jury found him guilty on one count of conspiracy to commit securities fraud and two counts of securities fraud.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Court finds “pharma bro” Martin Shkreli caused losses of more than $10M
The losses Martin Shkreli caused through securities fraud mean he could face several years in prison when he is sentenced next month.
-
Former attorney to pharma bro Martin Shkreli found guilty in fraud scheme
Evan Greebel acted as outside counsel for pharma company Retrophin from 2012 to 2014. Prosecutors alleged during that time Greebel assisted Martin Shkreli in using Retrophin’s assets to pay investors in unrelated hedge funds run by Shkreli through the use of phony settlement and consulting agreements.
-
The best stories of 2017
From good news to bad news, 2017 was chock-full of noteworthy stories. But a few stood out among the rest. These are the five most-read articles published in 2017.
-
Breaking: Martin Shkreli’s Clinton threat lands him in jail
A judge has revoked bail for the pharma bro, who is waiting to be sentenced for securities fraud, over comments he made on Facebook offering a $5,000 bounty for samples of hair from former Secretary of State and presidential candidate Hillary Clinton.
-
Shkreli found guilty on three counts of securities fraud (Updated)
After a drawn out week of deliberations, the now infamous “Pharma bro” Martin Shkreli has been found guilty on three out of eight counts heard in a Brooklyn Court.
-
Prosecutors want Martin Shkreli to just shut the hell up
Although he has been “banned” from Twitter, by Twitter, Martin Shkreli is allegedly using other accounts to Tweet about the trial. He’s also holding impromptu press conferences.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
